dexamethasone - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.19 [0.38, 3.72]< 10%1 study (1/-)38.6 %NAnot evaluable crucial-
deaths 0.99 [0.75, 1.32]< 10%3 studies (3/-)51.6 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.66 [0.43, 1.02]< 10%1 study (1/-)96.9 %NAnot evaluable important-
mechanical ventilation 1.38 [0.45, 4.20]< 10%1 study (1/-)28.6 %NAnot evaluable important-
radiologic improvement (14-day) 4.89 [1.15, 20.79]> 10%1 study (1/-)98.4 %NAnot evaluable important-

safety endpoints 00

serious adverse events 0.53 [0.17, 1.62]< 10%1 study (1/-)86.8 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.